By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MediciNova, Inc. 

4350 La Jolla Village Drive, Suite 950

San Diego  California  92122  U.S.A.
Phone: 858-373-1500 Fax: 858-373-7000


SEARCH JOBS


Industry
Biotechnology






Company News
MediciNova, Inc. Announces FDA Granted Orphan Drug Designation To MN-001 (Tipelukast) For Idiopathic Pulmonary Fibrosis (IPF) 10/23/2014 7:20:32 AM
MediciNova, Inc. Receives Feedback From FDA Regarding Study Protocol For Phase 2 Trial Of MN-001 (Tipelukast) In NASH 10/9/2014 7:35:14 AM
MediciNova, Inc.'s MN-001 (Tipelukast) NASH Abstract Selected For Late-Breaking Session At The 65th Annual American Association for Study of Liver Diseases Meeting In Boston 10/7/2014 7:26:14 AM
Overview Of MediciNova, Inc.''s Clinical Trial Of MN-166 (Ibudilast) In ALS To Be Presented At The 13th Annual NEALS Meeting 9/30/2014 7:27:58 AM
MediciNova, Inc. Provides Update On Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 9/24/2014 7:21:14 AM
MediciNova, Inc. Announces New NIDA Grant For MN-166 (Ibudilast) In Opioid Dependence 9/8/2014 7:42:08 AM
MediciNova, Inc. To Present Data On MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF) 9/2/2014 7:55:20 AM
MediciNova, Inc. To Initiate Clinical Trial Of MN-166 (Ibudilast) In ALS 8/26/2014 7:16:24 AM
MediciNova, Inc. Shows Off Positive Phase 2a Study Of Ibudilast 8/19/2014 6:16:00 AM
MediciNova, Inc. Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Nonalcoholic Fatty Liver Disease 8/11/2014 5:23:23 PM
12345678910...
//-->